[{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Epirium \/ Not Applicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Not Applicable"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Epicatechin","moa":"Mitochondrial protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Piramal Pharma Solutions \/ Epirium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Epirium"}]

Find Clinical Drug Pipeline Developments & Deals for Epicatechin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.

                          Brand Name : EPM-01

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 27, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Epirium

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystrophy.

                          Brand Name : EPM-01

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 12, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 14, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank